Everolimus Price Forecast to 2025

Everolimus (Everolimus) is an oral mTOR inhibitor that is widely used in the treatment of various types of cancer, especially advanced and metastatic breast cancer, renal cell carcinoma, gastrointestinal stromal tumors, etc. As a targeted therapy drug, everolimus can precisely act on the mTOR signaling pathway of cancer cells, thereby inhibiting the growth and expansion of tumor cells. The therapeutic scope of everolimus is not limited to cancer. It is also used to treat certain types of neurological diseases, rejection after organ transplantation, etc., and has broad application prospects.

The price of everolimus varies by region and manufacturer. Everolimus’ original drug, Everolimus, has been launched in the Chinese market and has been included in medical insurance. In the domestic market, the common specifications of everolimus are 2.5 mg 30 tablets and 5 mg 30 tablets, and the price per box is about 3,000 yuan. The market price of the drug may be affected by different factors in the future, such as changes in medical insurance reimbursement policies and market demand.

In overseas markets, generic versions of everolimus have also been approved for marketing. The ingredients of the generic version of everolimus are the same as the original drug, and common generic versions include versions from India and Laos. The price of the Indian version of everolimus is relatively low. For example, the price of 10 tablets of 5 mg is between RMB 700 and RMB 800, while the price of 10 tablets of 10 mg is around RMB 1,200 to RMB 1,800. The price of the Laotian version of everolimus is also relatively affordable. The price of 5 mg 30 tablets is about 800 yuan, and the price of 10 mg 30 tablets is about 1,700 yuan.

With the emergence of generic versions, the price of everolimus is expected to fall further, which will allow more patients to benefit from the drug. Especially against the background that cancer treatment increasingly relies on targeted drugs, the market demand for everolimus remains strong.

Reference materials:https://www.drugs.com/everolimus.html